Aptus Capital Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$48.5M Sell
52,722
-3,949
-7% -$4M 0.38% 53
2025
Q4
$60.9M Buy
56,671
+1,877
+3% +$1.79M 0.44% 48
2025
Q3
$41.8M Buy
54,794
+1,354
+3% +$1.01M 0.3% 67
2025
Q2
$41.7M Buy
53,440
+4,573
+9% +$3.55M 0.34% 63
2025
Q1
$40.4M Buy
48,867
+4,687
+11% +$3.9M 0.42% 56
2024
Q4
$34.1M Buy
44,180
+8,703
+25% +$7.21M 0.36% 62
2024
Q3
$31.4M Buy
35,477
+5,180
+17% +$4.66M 0.47% 53
2024
Q2
$27.4M Buy
30,297
+5,454
+22% +$4.36M 0.48% 49
2024
Q1
$19.3M Buy
24,843
+1,498
+6% +$1.07M 0.36% 61
2023
Q4
$13.6M Sell
23,345
-23
-0.1% -$13.4K 0.37% 69
2023
Q3
$12.6M Sell
23,368
-1,126
-5% -$580K 0.34% 66
2023
Q2
$11.5M Sell
24,494
-5,327
-18% -$2.23M 0.28% 82
2023
Q1
$10.2M Sell
29,821
-4,660
-14% -$1.57M 0.28% 78
2022
Q4
$12.6M Buy
34,481
+757
+2% +$268K 0.39% 55
2022
Q3
$10.9M Buy
33,724
+8,609
+34% +$2.73M 0.26% 54
2022
Q2
$8.14M Buy
25,115
+10,017
+66% +$3.01M 0.21% 73
2022
Q1
$4.32M Buy
15,098
+2,600
+21% +$669K 0.11% 112
2021
Q4
$3.45M Buy
12,498
+1,544
+14% +$391K 0.1% 127
2021
Q3
$2.53M Buy
10,954
+882
+9% +$218K 0.07% 140
2021
Q2
$2.31M Buy
10,072
+2,768
+38% +$556K 0.07% 128
2021
Q1
$1.36M Sell
7,304
-863
-11% -$169K 0.05% 180
2020
Q4
$1.38M Buy
8,167
+631
+8% +$94.2K 0.06% 139
2020
Q3
$1.11M Sell
7,536
-14,591
-66% -$2.26M 0.06% 142
2020
Q2
$3.63M Buy
22,127
+5,780
+35% +$887K 0.23% 68
2020
Q1
$2.27M Buy
16,347
+14,024
+604% +$1.93M 0.2% 83
2019
Q4
$305K Buy
2,323
+217
+10% +$25.2K 0.02% 301
2019
Q3
$235K Hold
2,106
0.01% 343
2019
Q2
$233K Hold
2,106
0.03% 305
2019
Q1
$273K Buy
+2,106
New +$256K 0.05% 267

Other funds holding LLY

Aptus Capital Advisors's LLY Position: Q1 2026 in Review

Aptus Capital Advisors reduced its Eli Lilly (LLY) stake by 7% in Q1 2026, selling an estimated $4M and leaving 52,722 shares worth $48.5M. The position accounts for 0.38% of the portfolio, ranked #53.

Aptus Capital Advisors first reported a position in LLY in Q1 2019 and has held it in 29 quarters since. The position peaked at $60.9M in Q4 2025. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Aptus Capital Advisors held 52,722 shares of Eli Lilly worth $48.5M as of Q1 2026.
  • Aptus Capital Advisors sold 3,949 Eli Lilly shares in Q1 2026, an estimated $4M.
  • Eli Lilly made up 0.38% of Aptus Capital Advisors's portfolio in Q1 2026, its #53 holding.
  • Aptus Capital Advisors first reported a position in Eli Lilly in Q1 2019 and has held it in 29 quarters since.
  • Aptus Capital Advisors's Eli Lilly position peaked at $60.9M in Q4 2025.
  • 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Aptus Capital Advisors's 13F filing for Q1 2026, filed 11 May 2026.